FDA Approves Actemra to Treat Giant Cell Arteritis

Share this content:
FDA Approves Actemra to Treat Giant Cell Arteritis
FDA Approves Actemra to Treat Giant Cell Arteritis

MONDAY, May 22, 2017 (HealthDay News) -- The injected drug Actemra (tocilizumab) has been approved by the U.S. Food and Drug Administration to treat adults with giant cell arteritis.

Actemra was evaluated in clinical studies involving 251 patients with giant cell arteritis. Compared to patients receiving placebo with a standardized prednisone regimen, a higher number of patients receiving subcutaneous Actemra with a standardized prednisone regimen achieved sustained remission. Relative to placebo, the cumulative prednisone dose was lower in patients treated with Actemra.

The drug will carry a boxed label warning of the possibility of serious infections. For that reason, live vaccines should be avoided while taking the drug, the FDA said. And Actemra should be used with caution among patients at increased risk of gastrointestinal perforation or dangerous allergic-like hypersensitivity reactions, the agency added.

The Hoffmann-La Roche drug was first approved in 2010 for moderately-to-severely active rheumatoid arthritis. The company is based in Basel, Switzerland.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

24-Hour Primary Care Clinics Would Improve Continuity of Care

24-Hour Primary Care Clinics Would Improve Continuity of ...

Model involving multiple doctors working shifts in their own clinic offers many benefits

Repeat BP Reading Needed in Children With Initial High Result

Repeat BP Reading Needed in Children With Initial ...

Based on initial reading, more than half of children would have incorrect classification

Brochure Can Improve Opioid Disposal Rates After Surgery

Brochure Can Improve Opioid Disposal Rates After Surgery

Patients more likely to dispose of unused opioids after getting information and recommendations

is free, fast, and customized just for you!

Already a member?

Sign In Now »